Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Kaphan E, Germi R, Bailly S, Bulabois CE, Carré M, Cahn JY, Thiebaut-Bertrand A. Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation. Transpl Infect Dis 2021;23:e13601. [PMID: 33724650 DOI: 10.1111/tid.13601] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 02/01/2021] [Accepted: 02/08/2021] [Indexed: 11/28/2022]

For:	Kaphan E, Germi R, Bailly S, Bulabois CE, Carré M, Cahn JY, Thiebaut-Bertrand A. Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation. Transpl Infect Dis 2021;23:e13601. [PMID: 33724650 DOI: 10.1111/tid.13601] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 02/01/2021] [Accepted: 02/08/2021] [Indexed: 11/28/2022]

Number

Cited by Other Article(s)

Juárez A, Salas MQ, Pedraza A, Suárez-Lledó M, Rodríguez-Lobato LG, Solano MT, Serrahima A, Nomdedeu M, Cid J, Lozano M, Charry P, Arcarons J, Llobet N, Rosiñol L, Fernández-Avilés F, Rovira M, Martínez C. Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study. Cancers (Basel) 2024;16:2567. [PMID: 39061206 PMCID: PMC11274764 DOI: 10.3390/cancers16142567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2024] [Revised: 07/03/2024] [Accepted: 07/16/2024] [Indexed: 07/28/2024] Open

Affiliation(s)

Alex Juárez Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.)
María Queralt Salas Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.)
Alexandra Pedraza Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.P.); (M.N.)
María Suárez-Lledó Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.) August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.)
Luís Gerardo Rodríguez-Lobato Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.) August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.)
María Teresa Solano Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.)
Anna Serrahima Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.)
Meritxell Nomdedeu Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.P.); (M.N.)
Joan Cid August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Miquel Lozano August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Paola Charry August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Jordi Arcarons Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.)
Noemí Llobet Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.)
Laura Rosiñol Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.) August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Institute Josep Carreras, Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Francesc Fernández-Avilés Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.) August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Institute Josep Carreras, Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Montserrat Rovira Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.) August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Institute Josep Carreras, Hospital Clínic de Barcelona, 08036 Barcelona, Spain
Carmen Martínez Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Disease (ICAMS), Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (A.J.); (M.Q.S.); (M.S.-L.); (L.G.R.-L.); (M.T.S.); (A.S.); (J.A.); (N.L.); (L.R.); (F.F.-A.); (M.R.) August Pi i Sunyer Biomedical Research Institute—IDIBAPS, 08036 Barcelona, Spain; (J.C.); (M.L.); (P.C.) Institute Josep Carreras, Hospital Clínic de Barcelona, 08036 Barcelona, Spain

Collapse

Sayýn S, Yýldýrým M, Cömert M, Uğur B, Yýlmaz EŞ, Avcu F, Ural AU, Aylı M. Comparison of Infectious Complications in Patients Receiving High-Dose Cyclophosphamide as GvHD Prophylaxis After Transplantation From A 9/10 HLA-Matched Unrelated Donor with Standard GvHD Prophylaxis After Transplant From A Fully Matched Related Donor. Mediterr J Hematol Infect Dis 2024;16:e2024016. [PMID: 38468829 PMCID: PMC10927186 DOI: 10.4084/mjhid.2024.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 02/05/2024] [Indexed: 03/13/2024] Open

Moss JE, Muller WJ. BK virus-associated hemorrhagic cystitis in pediatric stem cell transplantation: a case report and scoping review. Front Pediatr 2024;11:1267678. [PMID: 38406625 PMCID: PMC10884191 DOI: 10.3389/fped.2023.1267678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Accepted: 12/29/2023] [Indexed: 02/27/2024] Open

Abstract

Introduction

BK virus-associated hemorrhagic cystitis (BK-HC) is a debilitating and poorly understood complication of hematopoietic stem cell transplantation (SCT). Hematuria, dysuria, and other symptoms associated with BK-HC are common in the immediate post-SCT period, making BK-HC difficult to distinguish from other conditions presenting with these symptoms. Despite published criteria for diagnosis, the degree to which these criteria are consistently applied to either clinical diagnosis or to studies informing BK-HC management is unclear. We present a case of BK-HC in a pediatric SCT recipient, and discuss the challenges associated with treatment in the absence of rigorous data to inform clinical management.

Methods

We reviewed all cases of BK viruria at our center in patients undergoing SCT between January 2015 and December 2019. We then performed a scoping review of publications in PubMed addressing BK-HC, specifically focusing on how BK-HC was defined. Publications using the keywords "BK polyomavirus" and "hemorrhagic cystitis" were included if they involved a clinical study of SCT recipients and a full-text article was available in English. Case reports were excluded. Analysis focused on whether BK-HC was explicitly defined and whether the definition incorporated elements of diagnostic criteria published by European Conference on Infections in Leukemia (ECIL).

Results

A total of 30 studies published between January 2018 and 30 June 2021 met criteria for review, including 4 clinical trials, 7 prospective observational studies, and 19 retrospective observational studies. Fifteen of these studies included pediatric patients (7 pediatric only, 8 combined adult and pediatric). Of the 30 publications, 19 included a definition of either BK-HC or BK cystitis, with only five using ECIL criteria, all of which were observational studies. Multiple interventions are described for treatment of BK-HC, including cidofovir, leflunomide, quinolones, hyperbaric oxygen, keratinocyte growth factor, and BK-specific cytotoxic T lymphocytes. However, evidence to support efficacy for any of these interventions is lacking.

Discussion

Although BK-HC is a well-known complication of SCT, evidence to support available treatment options is limited. Well-controlled studies that incorporate clear diagnostic criteria are needed to better define the risk factors, natural history, and ideal interventions.

Collapse

Duléry R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, Calabro M, Van de Wyngaert Z, Bonnin A, Ledraa T, Legrand O, Labopin M, Capderou E, Cohen A, Ederhy S, Mohty M. Reduced post-transplant cyclophosphamide dose with antithymocyte globulin in peripheral blood stem cell haploidentical transplantation. Bone Marrow Transplant 2023;58:1215-1222. [PMID: 37596473 DOI: 10.1038/s41409-023-02085-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 08/01/2023] [Accepted: 08/09/2023] [Indexed: 08/20/2023]

Affiliation(s)

Rémy Duléry Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France. INSERM, UMRs 938, Centre de recherche Saint Antoine (CRSA), Paris, France.
Florent Malard Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France INSERM, UMRs 938, Centre de recherche Saint Antoine (CRSA), Paris, France
Eolia Brissot Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France INSERM, UMRs 938, Centre de recherche Saint Antoine (CRSA), Paris, France
Anne Banet Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Simona Sestili Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Ramdane Belhocine Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Martina Calabro Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Zoé Van de Wyngaert Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Agnès Bonnin Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Tounes Ledraa Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Ollivier Legrand Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France INSERM, UMRs 938, Centre de recherche Saint Antoine (CRSA), Paris, France
Myriam Labopin Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation (EBMT) Paris Study Office/CEREST-TC, Paris, France
Elodie Capderou Sorbonne University, UNICO-GRECO Cardio Oncology Program, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Ariel Cohen Sorbonne University, UNICO-GRECO Cardio Oncology Program, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Stéphane Ederhy Sorbonne University, UNICO-GRECO Cardio Oncology Program, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
Mohamad Mohty Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France INSERM, UMRs 938, Centre de recherche Saint Antoine (CRSA), Paris, France

Collapse

Zhou X, Zhang S, Fan J, Zhu X, Hu S. Risk factors for BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Clin Transplant 2023;37:e15121. [PMID: 37676427 DOI: 10.1111/ctr.15121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 08/24/2023] [Accepted: 08/30/2023] [Indexed: 09/08/2023]

Abstract

OBJECTIVE AND BACKGROUND

BK virus-associated hemorrhagic cystitis (BKV-HC) is an intractable complication leading to higher mortality and prolonged hospitalization among allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients. Therefore, identifying the potential risk factors of BKV-HC after allo-HCT is crucial to improve prognosis and for early prevention. However, the risk factors for BKV-HC remain debatable. Therefore, we conducted a systematic review and meta-analysis to identify the risk factors for BKV-HC, for early prevention of the occurrence of BKV-HC and to improve the quality of life and prognosis of allo-HCT recipients.

METHODS

We searched relevant studies from PubMed, EMBASE, and the Cochrane Library up to February 2023. The odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) of all risk factors were calculated to evaluate their effects on the occurrence of BKV-HC.

RESULTS

Overall, 11 studies involving 2556 allo-HCT recipients were included in this meta-analysis. All included studies were retrospective and published between 2013 and 2022. We found that male sex (OR = 1.32; 95% CI, 1.07-1.62; p = .009, I2 = 34%), haploidentical donor (OR = 1.84; 95% CI, 1.18-2.87; p = .007, I2 = 23%), myeloablative conditioning (OR = 1.76; 95% CI, 1.36-2.28; p < .0001, I2 = 45%), acute graft versus host disease (aGVHD) (OR = 2.73; 95% CI, 2.02-3.69; p < .0001, I2 = 46%), chronic graft versus host disease (cGVHD) (OR = 1.71; 95% CI, 1.12-2.60; p = .01, I2 = 0%), and cytomegalovirus (CMV) reactivation (OR = 3.13; 95% CI, 1.12-8.78; p = .03, I2 = 79%) were significantly associated with BKV-HC in the univariable analysis.

CONCLUSIONS

Our meta-analysis indicated that male sex, haploidentical donor, myeloablative conditioning, aGVHD, cGVHD, and CMV reactivation were potential risk factors for BKV-HC.

Collapse

Santos Carreira A, Salas MQ, Remberger M, Novitzky-Basso I, Law AD, Lam W, Pasic I, Mazzulli T, Cserti-Gazdewich C, Kim DDH, Michelis FV, Viswabandya A, Gerbitz A, Lipton JH, Kumar R, Hassan M, Mattsson J. Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2023;29:581.e1-581.e8. [PMID: 37437765 DOI: 10.1016/j.jtct.2023.07.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Revised: 06/10/2023] [Accepted: 07/03/2023] [Indexed: 07/14/2023]

Affiliation(s)

Abel Santos Carreira University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Maria Queralt Salas University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Hematopoietic Cell Transplant Unit, Department of Hematology, IDIBAPS, Hospital Clinic de Barcelona, Spain
Mats Remberger Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden
Igor Novitzky-Basso Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
Arjun Datt Law University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Wilson Lam University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Ivan Pasic University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Tony Mazzulli Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Department of Microbiology, Sinai Health System/University Health Network, Toronto, Ontario, Canada
Christine Cserti-Gazdewich University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Blood Transfusion Laboratory, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada
Dennis Dong Hwan Kim University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Fotios V Michelis University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Auro Viswabandya University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Armin Gerbitz University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Jeffrey Howard Lipton University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Rajat Kumar University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Moustapha Hassan Translational Research Centrum (TRACK), Karolinska University Hospital, Huddinge, Sweden; Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Karolinska Institutet- Huddinge, Sweden
Jonas Mattsson University of Toronto, Department of Medicine, Section of Medical Oncology and Hematology, Toronto, Ontario, Canada; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Collapse

Xie XT, Zhang YF, Zhang Y, Zeng HQ, Deng JC, Zhou K, Chen L, Luo Y, Lou SF. Decreased lymphocyte count before conditioning is associated with BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Int Immunopharmacol 2023;121:110515. [PMID: 37379706 DOI: 10.1016/j.intimp.2023.110515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/12/2023] [Accepted: 06/13/2023] [Indexed: 06/30/2023]

Abstract

BACKGROUND

BK virus-associated hemorrhagic cystitis (BKV-HC) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It can cause morbidity and may increase treatment-related mortality. Previous studies showed that the occurrence of BKV-HC was related to various factors. However, there are still many controversial factors. It is not clear whether BKV-HC will affect the long-term prognosis of patients.

OBJECTIVE

We aimed to identify risk factors for BKV-HC after allo-HSCT and evaluate the effect of BKV-HC on overall survival (OS) and progression- free survival (PFS) of patients.

STUDY DESIGN

We retrospectively analyzed the clinical data of 93 patients who underwent allo-HSCT. Univariate and multivariate analysis were used to identify risk factors for BKV-HC. The Kaplan-Meier method was used to estimate OS and PFS. A difference was considered statistically significant if P < 0.05.

RESULTS

A total of 24 patients developed BKV-HC. The median occurrence time of BKV-HC was 30 (range:8-89) days after transplantation, and the median duration was 25.5 (range:6-50) days. Multivariate logistic regression analysis indicated that peripheral blood lymphocyte count <1 × 10⁹/L before conditioning (OR = 4.705, P = 0.007) and haploidentical transplantation (OR = 13.161, P = 0.018) were independent risk factors for BKV-HC. The 3-year OS rate was 85.9% (95%CI:62.1%-95.2%) in the BKV-HC group and 73.1% (95%CI: 58.2%-88.0%) in the non-BKV-HC group. There was no significant difference between the two groups (P = 0.516). The 3-year PFS rate was 76.3% (95%CI: 57.9%-94.7%) in the BKV-HC group and 58.1% (95%CI: 39.5%-76.7%) in the non-BKV-HC group. There was no significant difference in the two groups (P = 0.459). The severity of BKV-HC was not related to the OS and PFS of the patients (P value was 0.816 and 0.501, respectively).

CONCLUSION

Haploidentical transplantation and decreased peripheral blood lymphocyte count before conditioning increased the risk of BKV-HC after allo-HSCT. The occurrence of BKV-HC after allo-HSCT and the severity of which did not affect OS and PFS of the patients.

Collapse

Wo S, Cirrone F, Al-Homsi AS. A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in Allogeneic Transplantation. Transplant Cell Ther 2023;29:210-211. [PMID: 36436781 DOI: 10.1016/j.jtct.2022.11.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 11/17/2022] [Indexed: 11/26/2022]

Uzay A, Gündoğdu Y, Koşan B, Yetiş T, Gür H, Okuturlar Y, Kartı SS. Daily low dose intravesical cidofovir for the treatment of BK virus associated hemorrhagic cystitis after allogeneic stem cell transplantation. J Infect Chemother 2022;29:67-71. [PMID: 36162643 DOI: 10.1016/j.jiac.2022.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 08/01/2022] [Accepted: 09/19/2022] [Indexed: 11/24/2022]

Ngo D, Samuels D, Chen J, Koller PB, Al Malki MM. A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplant Cyclophosphamide in an Allogeneic Transplant. Transplant Cell Ther 2022;28:349-354. [PMID: 35580733 DOI: 10.1016/j.jtct.2022.05.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 05/05/2022] [Accepted: 05/09/2022] [Indexed: 12/15/2022]